Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
The only FDA-approved treatment for COVID-19 added $873 million in the third quarter.
Full Article
Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
Motley Fool
0 shares
1 views
You might like
Related news coverage
NA Proactive news snapshot: Revive Therapeutics, KULR Technology, Lexaria Bioscience, TRACON Pharmaceuticals UPDATE …
Proactive Investors
Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) announced Monday that it has committed to 10 clinical sites in the US for its..
-
NA Proactive news snapshot: KWESST Micro Systems, WeedMD, Bragg Gaming Group, MGX Minerals, Phunware, Nextleaf Solutions, Candelaria Mining UPDATE…
Proactive Investors
-
NA Proactive news snapshot: BTU Metals, Vuzix Corporation, Bioasis Technologies, Cabral Gold, Klondike Gold UPDATE …
Proactive Investors
-
NA Proactive news snapshot: Cardiol Therapeutics, FansUnite Entertainment, Todos Medical, Lucky Minerals, GGX Gold, Flowr, 1933 Industries, KWESST UPDATE..
Proactive Investors
-
How SōRSE Technology is breaking the next frontier to test a cannabinoid-based cancer therapy
Proactive Investors
Advertisement
More coverage
NA Proactive news snapshot: Energy Fuels, PyroGenesis Canada, CleanSpark, Versus Systems, Avalon GloboCare, MGX Minerals UPDATE …
Energy Fuels Inc (NYSE:UUUU) (TSX:EFR), a leading producer of uranium and vanadium in the US, is applauding President Trump for..
Proactive Investors